GH analyst estimates
Guardant Health (GH) analyst ratings, the average price target and its range, and every firm's latest call.
GH analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 27, 2026 | BTIG | Guardant Health (GH) PT Raised to $210 at BTIG, remains Top Pick | $210.00 |
| Oct 12, 2026 | Morgan Stanley | Guardant Health price target raised to $200 from $185 at Morgan Stanley | $200.00 |
| Oct 7, 2026 | Barclays | Guardant Health price target raised to $220 from $200 at Barclays | $220.00 |
| Oct 1, 2026 | Guggenheim | Guardant Health price target raised to $200 from $190 at Guggenheim | $200.00 |
| Sep 10, 2026 | Bernstein | Bernstein SocGen Group Reiterates Outperform Rating on Guardant Health (GH) | $210.00 |
| Sep 9, 2026 | UBS | Guardant Health assumed with a Buy at UBS | $225.00 |
| Sep 8, 2026 | Redburn Partners | Guardant Health initiated with a Buy at Rothschild & Co Redburn | $203.00 |
| Aug 4, 2026 | Piper Sandler | Guardant Health price target raised to $193 from $135 at Piper Sandler | $193.00 |
| Aug 4, 2026 | Stephens | Guardant Health price target raised to $195 from $170 at Stephens | $195.00 |
| Aug 4, 2026 | Morgan Stanley | Guardant Health price target raised to $185 from $175 at Morgan Stanley | $185.00 |
| Jul 31, 2026 | Mizuho Securities | Guardant Health (GH) PT Raised to $200 at Mizuho | $200.00 |
| Jul 31, 2026 | Goldman Sachs | Guardant Health price target raised to $210 from $185 at Goldman Sachs | $210.00 |
| Jul 31, 2026 | Stifel Nicolaus | Guardant Health (GH) PT Raised to $180 at Stifel | $180.00 |
| Jul 31, 2026 | RBC Capital | Guardant Health (GH) PT Raised to $210 at TD Cowen | $210.00 |
| Jul 31, 2026 | RBC Capital | Guardant Health price target raised to $200 from $185 at RBC Capital | $200.00 |
- 23 firms rate GH: 23 buy, 0 hold, 0 sell.
- The average price target is $204.31 from 13 analysts, from $180.00 to $225.00.
Updated 2026-11-02 17:52 UTC